Table 3.

Treatment and outcome characteristics

CharacteristicAll patients (N = 71)RT only (n = 36)Combined therapy (n = 29)RT-only vs combined therapy, PSystemic therapy (n = 6)
Treatment
 Systemic only6 (9)
 Radiation only36 (51)
 Combined29 (41)
Treatment era
 Before 20008 (11)6 (17)2 (7).4440
 2000–201030 (42)14 (39)11 (38)5 (83)
 2011–201733 (47)16 (44)16 (55)1 (17)
Systemic therapy (n = 35)
 R-ABVD5 (7)4 (14)1 (17)
 R-CHOP22 (31)19 (66)3 (50)
 Rituximab5 (7)3 (10)2 (33)
 Other3 (4)3 (10)
RT (n = 65)
 EFRT12 (17)9 (25)3 (10).088
 IFRT20 (28)13 (36)7 (24)
 ISRT33 (47)14 (39)19 (66)
RT (n = 65)
 3-Dimensional39 (60)27 (75)12 (41).010
 Intensity-modulated RT26 (40)9 (25)17 (59)
Radiation dose (n = 65)
 Median (range), Gy30.6 (21.6-40.0)36 (30-40)30.6 (21.6-40)
 >30.6 Gy32 (49)26 (72)6 (21)<.001
 ≤30.6 Gy33 (51)10 (28)23 (79)
Death
 Yes6 (8)3 (8)2 (7)1 (17)
 No65 (92)33 (92)27 (93)5 (83)
Relapse or progression
 Yes15 (21)8 (22)5 (17)2 (33)
 No56 (79)28 (78)24 (83)4 (67)
Local relapse
 Yes2 (3)002 (33)
 No69 (97)36 (100)29 (100)4 (67)
Distant relapse
 Yes13 (18)8 (22)5 (17)0
 No58 (82)28 (78)24 (83)6 (100)
Transformation
 Yes2 (3)1 (3)1 (3).8760
 No69 (97)35 (97)28 (97)
Second malignancy
 Yes8 (11)3 (8)5 (17).2770
 No63 (89)33 (92)24 (83)6 (100)
Median follow-up (95% CI), y*6.1 (5.0-7.2)6.1 (3.3-8.9)4.4 (0.42–8.4).1747.5 (4.0-11.0)
  • Unless otherwise noted, all data are n (%).

  • * P value for comparison of all 3 groups is .341.